Savara, Inc. (SVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.370.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SVRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SVRA — officer change
Dated 2026-06-08
Chief Financial and Operating Officer — Robert Lutz: Robert Lutz was promoted to Chief Financial and Operating Officer, succeeding David Lowrance who resigned due to health reasons.
Why it matters: Leadership changes can affect company strategy and performance. Investors will want to see how this transition unfolds.
Watch forThe company shares good news about changes or money gains with the new CFO and COO.
Also watch forThe company has issues or loses money after the leadership change.
Why it matters: Moving can help operations and boost employee morale. A good move may show positive change.
Supportive ifThe headquarters move is done well, with good feedback from workers.
Worry ifThere are delays or problems during the move.
Why it matters: Using the loan well can help growth and operations. This affects financial stability.
Supportive ifThe company will use the $105M term loan for growth projects by the next earnings call.
Worry ifThe company does not use the term loan well. This causes operational problems.
Why it matters: A rebound in healthcare growth could help Savara's performance.
Supportive ifHealthcare sector revenue growth speeds up back toward over 10%.
Worry ifHealthcare sector revenue growth keeps slowing below current levels.
Why it matters: Leadership changes can affect company plans and how well it works.
Watch forGood performance results or plans announced by the new CFO.
Also watch forThere are bad results or mistakes. This happened after the leadership change.
Why it matters: The move could help operations and boost employee morale. Delays may show problems.
Supportive ifThe new office space is fully operational as planned by July 1, 2026.
Worry ifDelays or problems with the move could hurt operations.
Why it matters: How Savara uses the loan will show if it can improve. Bigger losses suggest it has trouble using the loan well.
Worry ifIf operating income goes up, it shows good use of the loan.
Less concerning ifIf operating income goes down, it shows poor use of the loan.
Why it matters: Using this loan for growth can signal financial health and operational expansion. It is key for future projects.
Supportive ifThe company shares details about projects paid for by the $105M loan.
Worry ifThe company fails to utilize the term loan for growth or operational needs.
Why it matters: Increasing shares can attract talent and align incentives. A lack of progress may hinder recruitment.
Supportive ifThey announced the approval or start of the share increase for the incentive plan.
Worry ifNo progress or rejection of the shares increase proposal.
Why it matters: Successful relocation could enhance operations and attract talent. This is key for growth.
Supportive ifAnnouncement of completion of the headquarters move to Yardley, PA.
Worry ifDelay or cancel the plan to move the headquarters.
Why it matters: The new CFO's plans can impact financial management and growth strategy. Leadership changes can shift company direction.
Watch forThe new CFO presents a clear growth strategy in the next earnings call on August 12, 2026.
Also watch forNo clear strategic direction is presented by the new CFO in the next earnings call.
Why it matters: Changing the loan agreement can help with finances and support growth.
Supportive ifPublic announcement that the loan agreement has been changed.
Worry ifNot changing the loan agreement or having bad terms.
Why it matters: FDA approval is crucial for future revenue. A positive decision can boost investor confidence.
Supportive ifFDA grants approval for MOLBREEVI by the March 31, 2027 deadline.
Worry ifFDA denies approval or delays the decision past March 31, 2027.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $462 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,199 loss on $10,000 · 32.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.